• EZ Cap™ Cas9 mRNA (m1Ψ) Workflow Guide

  2026-09-19

  Build more controlled CRISPR-Cas9 experiments with a transient, Cap1-capped Cas9 mRNA workflow designed for efficient translation and reduced innate immune signaling. This guide connects practical handling and dose optimization with the reference study’s nuclear-export strategy for improving editing precision.

• PDHA1 Acetylation, Cuproptosis, and Enzalutamide Resistance

  2026-09-19

  This study identifies PDHA1 acetylation signaling as a metabolic–epigenetic axis that suppresses cuproptosis and weakens enzalutamide activity in castration-resistant prostate cancer. Its findings connect acetyl-CoA production, H3K27ac, SLC7A11-driven glutathione synthesis, and copper handling, suggesting that PDHA1 targeting may help restore anti-androgen sensitivity in resistant disease.

• Mitoxantrone: Mechanism, Resistance & Research Use

  2026-09-18

  Mitoxantrone is a topoisomerase II inhibitor and anticancer research compound that damages DNA through intercalation and stabilization of the DNA–topoisomerase II complex. Mitozantrone is a spelling variant used in some searches; this article uses the standard name, Mitoxantrone, and explains ABCG2-mediated resistance, product handling, and assay integration.

• IWP-2 Wnt Production Inhibitor Workflow

  2026-09-17

  Build reproducible Wnt pathway experiments with IWP-2 by pairing Porcupine inhibition with orthogonal transcriptional, phenotypic, and apoptosis readouts. The workflow separates literature-backed product performance from practical optimization, helping researchers move from gastric cancer models to carefully bounded cross-domain assay design.

• GDC-0068 (RG7440) Pan-AKT Inhibitor

  2026-09-17

  GDC-0068, also known as RG7440, is an ATP-competitive pan-AKT inhibitor that targets Akt1, Akt2, and Akt3. Product information supports its use as a research tool for studying PI3K/Akt/mTOR signaling, cell-cycle control, and preclinical tumor models, especially those with PTEN loss or PI3K pathway activation.

• HO-1, ROS, and HBV Replication: ICAA Study

  2026-09-16

  A recent Antiviral Research study shows that isochlorogenic acid A suppresses HBV at multiple stages, including transcription, genome production, cccDNA maintenance, capsid formation, and envelopment. Its mechanistic contribution is the connection of these antiviral effects with HO-1 upregulation and altered intracellular ROS, while also identifying viral protein thiol chemistry as a possible link to defective morphogenesis.

• Nitrocefin Workflows for β-Lactamase Assays

  2026-09-16

  Nitrocefin converts β-lactamase hydrolysis into a visible and spectrophotometric signal, making it useful for resistance profiling, mechanistic enzyme studies, and inhibitor screening. This workflow-focused guide connects assay setup and troubleshooting with the 2024 structure-guided peptide discovery study targeting TEM-1 β-lactamase.

• Tin Mesoporphyrin IX: HO Assay Workflows

  2026-09-15

  A practical guide to using Tin Mesoporphyrin IX (chloride) as a direct pharmacological probe of heme oxygenase activity. The workflow connects enzyme inhibition with metabolic, ROS, and HBV-related assays while emphasizing controls, dose selection, and troubleshooting.

• D-Lin-MC3-DMA: From LNP Design to Assays

  2026-09-15

  Dlin-MC3-DMA is an ionizable cationic liposome lipid for siRNA and mRNA delivery. This article explains how its chemistry, formulation variables, and machine-learning evidence can guide more informative LNP assay decisions.

• TAK-242: A Translational Lens on TLR4 Biology

  2026-09-14

  TAK-242 (Resatorvid) offers translational researchers a selective way to interrogate TLR4 signaling, connect LPS-driven inflammation with neuroimmune outcomes, and distinguish receptor-proximal biology from downstream inflammatory effects. This thought-leadership guide integrates mechanistic rationale, evidence from an aged-rat cognitive model, practical protocol design, and strategic considerations for advancing neuroinflammation research.

• Z-VAD-FMK in Resistant Lung Cancer Assays

  2026-09-14

  Z-VAD-FMK enables causal testing of caspase dependence in drug-resistant lung cancer models. This guide connects apoptosis inhibition with ferroptosis-aware assay design and insights from a 2025 EGFR-mutant lung adenocarcinoma study.

• Cabazitaxel Workflow for Resistant Tumor Models

  2026-09-13

  Cabazitaxel (XRP6258, SKU B2157) provides a practical antiproliferative agent in cancer research focused on microtubule dynamics disruption, including taxane-resistant and P-glycoprotein-expressing models. It is intended for DMSO- or ethanol-based workflows, not direct aqueous preparation, and prepared solutions should be used promptly rather than stored long term.

• Bestatin as a Chemical Genetics Tool for Jasmonate Signaling

  2026-09-12

  Zheng and colleagues showed that the aminopeptidase inhibitor bestatin can selectively activate jasmonate responses in tomato and Arabidopsis, while using its root-growth phenotype to isolate bestatin-resistant mutants. The study established a chemical-genetics framework that links pharmacological perturbation, transcriptomics, developmental phenotyping, and mutant analysis to identify previously unrecognized components of jasmonate signaling.

• Dlin-MC3-DMA for LNP RNA Delivery

  2026-09-12

  Dlin-MC3-DMA supports high-potency siRNA and mRNA nanoparticle workflows, from hepatic gene silencing to cell-state-sensitive microglia assays. This practical guide connects formulation design, machine-learning-assisted screening, and troubleshooting for more reproducible RNA delivery experiments.

• Fluorouracil and Wnt: A Translational Playbook

  2026-09-11

  Fluorouracil is more than a viability benchmark. This thought-leadership guide connects its thymidylate synthase mechanism with Wnt-driven tumor biology, immune context, experimental design, and translational decision-making in solid tumor research.

8704 records 1/581 page Next 12345 下5页 Last page